Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - PubMed (original) (raw)
Clinical Trial
. 2009 Dec 24;114(27):5444-53.
doi: 10.1182/blood-2009-03-213298. Epub 2009 Sep 28.
Theodore A Gooley, Joseph Rajendran, Darrell R Fisher, Wendy A Wilson, Brenda M Sandmaier, Dana C Matthews, H Joachim Deeg, Ajay K Gopal, Paul J Martin, Rainer F Storb, Oliver W Press, Frederick R Appelbaum
Affiliations
- PMID: 19786617
- PMCID: PMC2798861
- DOI: 10.1182/blood-2009-03-213298
Clinical Trial
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M Pagel et al. Blood. 2009.
Abstract
We conducted a study to estimate the maximum tolerated dose (MTD) of (131)I-anti-CD45 antibody (Ab; BC8) that can be combined with a standard reduced-intensity conditioning regimen before allogeneic hematopoietic cell transplantation. Fifty-eight patients older than 50 years with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) were treated with (131)I-BC8 Ab and fludarabine plus 2 Gy total body irradiation. Eighty-six percent of patients had AML or MDS with greater than 5% marrow blasts at the time of transplantation. Treatment produced a complete remission in all patients, and all had 100% donor-derived CD3(+) and CD33(+) cells in the blood by day 28 after the transplantation. The MTD of (131)I-BC8 Ab delivered to liver was estimated to be 24 Gy. Seven patients (12%) died of nonrelapse causes by day 100. The estimated probability of recurrent malignancy at 1 year is 40%, and the 1-year survival estimate is 41%. These results show that CD45-targeted radiotherapy can be safely combined with a reduced-intensity conditioning regimen to yield encouraging overall survival for older, high-risk patients with AML or MDS. This study was registered at www.clinicaltrials.gov as #NCT00008177.
Figures
Figure 1
Estimated radiation absorbed doses per millicurie of 131I. Estimated radiation absorbed doses per millicurie of 131I administered for (A) all patients, (B) patients with AML in remission, in relapse, with refractory AML, and patients with high-risk MDS. Results are shown as mean ± SEM.
Figure 2
The fitted dose-toxicity curve from the observed data. The solid circles indicate the observed DLT rate at the appropriate dose, and the vertical line represents the dose associated with a DLT rate of 25% from the fitted curve.
Figure 3
Estimates of the probability of OS, DFS, NRM, and relapse among all patients who received a therapeutic dose of 131I-BC8 Ab, followed by TBI/FLU.
Figure 4
Estimates of the probability of OS, DFS, NRM, and relapse among patients treated at the MTD of 24 Gy of radiation delivered to the liver by the 131I-BC8 Ab, followed by TBI/FLU.
Comment in
- Increasing the punch of reduced-intensity transplants.
Ball ED. Ball ED. Blood. 2009 Dec 24;114(27):5410-1. doi: 10.1182/blood-2009-10-247569. Blood. 2009. PMID: 20035041 No abstract available.
References
- Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–4536. - PubMed
- Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–763. - PubMed
- Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89(8):3048–3054. - PubMed
- McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400. - PubMed
- Sandmaier BM, Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In: Blume KG, Forman SJ, editors. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Malden, MA: Blackwell Publishing Ltd; 2004. pp. 1164–1176.
Publication types
MeSH terms
Substances
Grants and funding
- K08 CA095448/CA/NCI NIH HHS/United States
- R01 CA109663/CA/NCI NIH HHS/United States
- P01 CA044991/CA/NCI NIH HHS/United States
- P01 CA078902/CA/NCI NIH HHS/United States
- P01 CA018029/CA/NCI NIH HHS/United States
- P30 CA015704/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous